Product Images Oxaliplatin

This is a report or chart showing the probability of DFS (Disease-Free Survival) and hazard ratio with confidence interval along with the stratified Logrank test. The chart also includes the number of events and patients at risk.*

This is a comparison of the median survival (in months) and percentage of patients surviving using different treatments for cancer. The treatments include Oxaliplatin for Injection and 5-FU/LV, Oxaliplatin for Injection + Irinotecan, and Irinotecan + 5-FU/LV. The results show that Oxaliplatin for Injection + 5-FU/LV has a median survival of 19.4 months, while Oxaliplatin for Injection + Irinotecan has a median survival of 17.6 months, and Irinotecan + 5-FU/LV has a median survival of 14.6 months. The log-rank test is used to compare the effectiveness of Oxaliplatin for Injection plus 5-FU/LV and Irinotecan plus 5-FU/LV.*

Oxaliplatin For Injection is a cytotoxic agent provided in a sterile lyophilized powder form for intravenous use only. Each vial contains 50mg of oxaliplatin, USP and 450mg of lactose monohydrate, NF as an inactive ingredient. The package insert should be referred to for usual dosage and reconstitution and dilution instructions. The reconstituted and diluted solutions should be stored between 15°-30°C with excursions allowed at 20°-25°C. The solution should not be reconstituted with sodium chloride or chloride-containing solutions. The unused portion should be discarded according to the instructions in the package insert. It is a prescription-only medicine distributed by XXX XXX XXX Co., Ltd., USA. The manufacturing is done by Qilu Pharmaceutical (Hainan) Co., Ltd. in China.*

This is a label for a medication called Oxaliplatin intended for intravenous use only. The label contains dosage information in milligrams per vial. The medication is identified as a cytotoxic agent and is indicated for use as a chemotherapy drug. The label also includes information about storage conditions and other safety precautions.*

This is a description for a medication called Oxaliplatin For Injection, which is a cytotoxic agent that comes in a single-dose vial of 100 mg. The medication is manufactured by Qiu Pharmaceutical in China and is distributed by an unidentified company. Before use, the medication must be reconstituted and diluted according to the instructions provided in the package insert. It is for intravenous use only, and healthcare professionals are advised not to reconstitute the medication with sodium chloride or chloride-containing solutions. Unused portions should be discarded, and storage instructions for reconstituted and diluted solutions are included in the package insert.*

Oxaliplatin is a cytotoxic agent that is intended for intravenous use only. It is available in single-dose vials of 100mg per vial. The medication should be reconstituted and diluted with sodium chloride before use. The carton label should indicate the strength of the medication in the vial. This text may be part of the medication's packaging or labeling.*